Judge OKs Glaxo's $75M Settlement Over Alleged Relafen Evergreening

Law360, New York (December 2, 2004, 12:00 AM EST) -- A federal judge has tentatively approved a $75 million settlement agreement between GlaxoSmithKline PLC and a group of consumers and third-party payors who claimed the U.K. drug maker broke antitrust law by trying to block generic competition for the arthritis drug Relafen.

U.S. District Court Judge William G. Young of the U.S. District Court for the District of Massachusetts last week granted preliminary approval of the proposed settlement, which was announced in May, according to Hagens Berman LLP, a law firm specializing in class-action lawsuits....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.